Characteristic Inflammatory Biomarkers in an Equine Model of Persistent Synovitis Induced By the Intra-Articular Administration of Monoiodoacetic Acid.
Authors: Fukuda Kentaro, Mita Hiroshi, Tamura Norihisa, Kuroda Taisuke, Kuwano Atsutoshi, Takahashi Toshiyuki, Sato Fumio
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Inflammatory Biomarkers in Equine MIA-Induced Synovitis Japanese researchers induced persistent synovitis in five horses by injecting monoiodoacetic acid into one carpal joint whilst using the contralateral joint as a saline control, then tracked inflammatory markers in synovial fluid and tissue over 42 days to characterise the condition's progression. Whilst acute inflammatory signs (elevated leukocytes, LDH, TNF-α and IL-6) peaked within the first two weeks before subsiding, chronic inflammatory markers persisted through day 35 and beyond, with histological examination at day 42 revealing active synovitis, osteoclasts, and significantly elevated expression of cartilage-degrading enzymes (MMP13, ADAMTS4) and bone-remodelling mediators (RANKL and Col1a2). The sustained elevation of these chronic inflammatory biomarkers in both synovial fluid and synovial tissue suggests they represent reliable indicators for evaluating therapeutic interventions against persistent joint inflammation. For practitioners managing equine arthritis and synovitis, these findings provide a robust panel of measurable markers—particularly MMP13, ADAMTS4, and RANKL—that could help differentiate active cartilage and bone degradation from resolution, potentially improving treatment decisions beyond clinical and ultrasound assessment alone. The MIA model itself offers researchers a validated tool for preclinical testing of anti-inflammatory therapies before clinical application in horses with naturally occurring joint disease.
Read the full abstract on PubMed
Practical Takeaways
- •This MIA-induced synovitis model provides a validated tool for equine veterinarians to test new anti-inflammatory treatments before clinical use, with characteristic biomarker patterns that can objectively measure drug effectiveness
- •Practitioners should recognize that acute clinical resolution (2 weeks) does not indicate complete resolution of inflammation—chronic biomarkers may persist for 5+ weeks, suggesting longer treatment or monitoring protocols may be needed
- •Specific synovial fluid and tissue markers (MMP13, ADAMTS4, RANKL, Col1a2) can be measured to objectively assess treatment response rather than relying solely on clinical signs and ultrasound findings
Key Findings
- •Acute inflammatory symptoms persisted for approximately 2 weeks before returning to control levels, while chronic inflammation indicators remained elevated until day 35
- •MMA-induced synovitis showed significantly higher expression of MMP13, ADAMTS4, RANKL, and Col1a2 compared to control joints
- •Histological examination on day 42 revealed persistent synovitis with osteoclast presence despite resolution of acute clinical signs
- •Inflammatory biomarkers in synovial fluid and tissue remained persistently elevated in chronic phase, suggesting utility for assessing anti-inflammatory drug efficacy